AIM General Clinical Guideline
OPEN THE GENERAL CLINICAL GUIDELINE EFFECTIVE AUGUST 17, 2020
AIM CLINICAL APPROPRIATENESS GUIDELINES FOR RADIATION ONCOLOGY
The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines.
AIM Clinical Appropriateness Guidelines for Radiation Oncology are developed through a rigorous process integrating evidence-based literature with expert physician review. Guidelines for radiation therapy, proton beam therapy, and radiopharmaceutical therapy are included below.
Access guidelines for Blue Cross and Blue Shield members in Illinois, Montana, New Mexico, Oklahoma and Texas, and Blue Cross Community CentennialSM, Medicaid Members in New Mexico here
AIM Clinical Appropriateness Guidelines for Radiation Oncology
The treatments addressed in the AIM Clinical Appropriateness Guidelines for Radiation Oncology include brachytherapy, intensity-modulated radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery.
OPEN THE GUIDELINES FOR RADIATION ONCOLOGY
COMING SOON RADIATION ONCOLOGY GUIDELINES EFFECTIVE MARCH 14, 2021
AIM Clinical Appropriateness Guidelines for Proton Beam Therapy
The treatment addressed in the AIM Clinical Appropriateness Guidelines for Proton Beam Therapy is proton beam therapy, also known as proton radiation therapy or proton radiotherapy.
OPEN THE GUIDELINES FOR PROTON BEAM THERAPY
COMING SOON PROTON BEAM THERAPY GUIDELINES EFFECTIVE MARCH 14, 2021
AIM Clinical Appropriateness Guidelines for Therapeutic Radiopharmaceuticals
The treatments addressed in the AIM Clinical Appropriateness Guidelines for Therapeutic Radiopharmaceuticals include the most commonly used radiopharmaceutical drug therapies for oncologic conditions.
OPEN THE GUIDELINES FOR THERAPEUTIC RADIOPHARMACEUTICALS
COMING SOON GUIDELINES FOR THERAPEUTIC RADIOPHARMACEUTICALS EFFECTIVE MARCH 14, 2021
DELIVERING CANCER CARE SAFELY AMID COVID-19
The COVID-19 pandemic has altered the delivery of cancer care. But clinical appropriateness and safety are still priorities. Our new resource center offers health care’s latest clinical guidance and insights to help ensure both.
Trouble viewing the guidelines?
To open our guidelines, your computer needs Adobe Reader, a free and trusted software that allows you to view PDFs.
CLINICAL GUIDELINES ACCESS
Accessing Clinical Guidelines and Cancer Treatment Pathways
By clicking on the “I accept” button below, I acknowledge I accept the following terms and conditions when accessing and using the Clinical Guidelines and Cancer Treatment Pathways:
AIM Specialty Health® (AIM) has developed proprietary Clinical Guidelines and Cancer Treatment Pathways (together with any updates, referred to collectively as the “Guidelines and Pathways”). The Guidelines and Pathways are designed to evaluate and direct the appropriate utilization of certain health care services. They are based on data from peer-reviewed scientific literature, from criteria developed by specialty societies, and from guidelines adopted by other health care organizations. Access to these Guidelines and Pathways is being provided for informational purposes only. Although AIM has a process for updating its Guidelines and Pathways on a regular basis, due to the rapidly evolving nature of medicine, these Guidelines and Pathways may not reflect the most current evidence on a particular service or treatment.
The Guidelines and Pathways are protected by copyright of AIM as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Guidelines and Pathways and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Guidelines and Pathways unless authorized in writing by AIM.
The Guidelines and Pathways do not constitute medical advice and/or medical care and do not guarantee results or outcomes. The Guidelines and Pathways are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines or Pathways is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The Guidelines and Pathways do not address coverage, benefit, or other plan specific issues.
The Guidelines and Pathways are provided “as is” without warranty of any kind, either expressed or implied. AIM disclaims all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Guidelines.
About the AIM Clinical Appropriateness Guidelines for Genetic Testing
The AIM Clinical Appropriateness Guidelines for Genetic Testing (with any updates, referred to as the “Genetic Testing Guidelines”) were developed by and used with permission from Informed Medical Decisions, Inc.
The Genetic Testing Guidelines are protected by copyright of Informed Medical Decisions, Inc., as permitted by and to the full extent of the law. These rights are not released, transferred, or assigned as a result of allowing access. You agree that you do not have any ownership rights to the Genetic Testing Guidelines and that you are expressly prohibited from selling, assigning, leasing, licensing, reproducing, or distributing the Genetic Testing Guidelines unless authorized in writing by Informed Medical Decisions.
AIM and Informed Medical Decisions, Inc., disclaim all responsibility for any consequences or liability attributable or related to any use, nonuse, or interpretation of information contained in the Genetic Testing Guidelines.